Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices (GMP) manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform integrates the company's proprietary PDAOAI technology with advanced robotics from its collaboration with TechForce Robotics, targeting pharmaceutical, biotechnology, and advanced therapeutics companies seeking to upgrade manufacturing operations.
The platform is designed to support electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions, and process monitoring. This initiative comes as the industry increasingly adopts automation to reduce errors and improve efficiency in drug production. Oncotelic also highlighted progress with its Deciparticle nanomedicine platform, including SAPU003, a clinical-stage intravenous everolimus program currently in a Phase 1b study.
The launch underscores Oncotelic's strategic pivot toward providing manufacturing services alongside its core drug development. By offering a digitized, AI-driven platform, the company aims to help partners streamline compliance with stringent regulatory standards. The collaboration with TechForce Robotics, which designs purpose-built robots for pharmaceutical manufacturing, adds a key automation component to the offering.
Oncotelic's PDAOAI platform, previously focused on drug discovery and lab automation, now extends to GMP manufacturing. The company's relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, further supports this expansion. With CEO Dr. Vuong Trieu holding 75 issued U.S. patents and over 500 patent applications, Oncotelic leverages a robust intellectual property portfolio to drive innovation in both therapeutics and manufacturing technology.
The implications for the industry are significant. As pharmaceutical companies face pressure to reduce costs and accelerate time-to-market, AI and robotics offer pathways to more consistent quality and faster production cycles. Oncotelic's platform could enable smaller biotech firms to access advanced manufacturing capabilities without heavy capital investment. For larger companies, digitizing GMP processes may help mitigate compliance risks and improve traceability.
Investors should note that Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu's leadership, which is advancing its own pipeline of drug candidates. This positions the company to benefit from both service revenue and potential product successes. The launch at BIO 2026, a major industry event, signals Oncotelic's commitment to scaling its manufacturing services and capturing a share of the growing market for AI-driven pharmaceutical production.
For more information, visit www.oncotelic.com and www.techforcerobotics.com.
